Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Study sponsor: Rigel Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-06-02Actual
Enrollment · participants123Actual
Source updated2023-12-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.